Acer Therapeutics Inc

Acer Therapeutics — Investor Presentation (September 2020)

47 slides from Acer Therapeutics's investor presentation, Sep 1, 2020

  1. Slide 1: Corporate Presentation September 2020

    Developing Therapeutics for the Treatment of Serious Rare and Life-Threatening Diseases with Significant Unmet Medical Needs Corporate Presentation September 2020 Nasdaq: ACER Exhibit 99.1

  2. Slide 2: Forward-looking Statements

    Forward-looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in

  3. Slide 3: Corporate Overview

    Corporate Overview Acer Therapeutics is a pharmaceutical company that acquires, develops and seeks to commercialize therapies for serious rare and life-threatening diseases with significant unmet medical needs Headquartered: Newton, MA Headcount: 20 Founded: December 2013 Public: September 2017 Cash

  4. Slide 4: Leadership Team

    Chris Schelling CEO & Founder 21 years; strategic commercial development & orphan Harry Palmin Chief Operating & Financial Officer 25+ years; corporate & finance experience Matt Seibt Chief Commercial Officer 22 years; sales, market access & product launch John Klopp Chief Technical Officer 18 years

  5. Slide 5: Investment Highlights

    Investment Highlights Acer’s pipeline includes four clinical-stage product candidates: Emetine for the treatment of COVID-19 ACER-001 (a taste-masked, immediate release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCD

  6. Slide 6: Clinical Pipeline

    Clinical Pipeline ACER *Initiation of Phase 2/3 trial subject to successful IND submission and clearance, and sufficient capital resources to fund the program **Requires bioequivalence (BE) trial under fed conditions ***Response received March 2020 denying appeal of the Complete Response Letter but

  7. Slide 7: Emetine overview: host-targeting antiviral therapy

    Host-targeting therapy with potent antiviral activity Restores cellular stress response, inhibiting viral replication Believed to be the only drug in development exploiting this MOA Mechanism of Action Global pandemic with no currently approved therapeutic options for COVID-19 outpatients Highly con

  8. Slide 8: Emetine background and history

    Emetine is one of the main alkaloids found in ipecacuanha (ipecac) root Clinically, emetine hydrochloride was originally marketed in the U.S. as a topical anti-infective in dental applications (ca 1890s by Eli Lilly and Company) Later, emetine hydrochloride for injection gained market adoption as a

  9. Slide 9: Emetine: Broad & Potent Antiviral Activity

    Clinically, emetine has been used to treat approximately 700 patients (including pediatrics) with viral hepatitis1 and varicella-zoster virus2 The antiviral activity of emetine in various in vitro/in vivo models is provided below: Emetine Emetine: Broad & Potent Antiviral Activity Virus Type Antivir

  10. Slide 10: Emetine: Uniquely Suited for COVID-19

    Emetine Emetine: Uniquely Suited for COVID-19 1 Bojkova, D. et al. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. Nature https://doi.org/10.1038/s41586-020-2332-7 (2020). 2 Ianevski et al. 2020 May. Antiviral options against SARS-CoV-2 infection. doi.org/10.1101/2020.05.12.091

  11. Slide 11: Emetine: Unique Mechanism of Action

    Emetine Emetine: Unique Mechanism of Action In high-density infected cells (A) emetine induces (1) nuclear translocation of RPS14 (2) followed by RPS14 binding to MDM2 (3 & 4) resulting in disruption of the interaction between MDM2-p53 (6) and MDM2- viral IE2 (5 & 7), and by RPS14 ubiquitination and

  12. Slide 12: Emetine: Safety

    Patients treated with 1 mg/kg/day emetine daily via SC injection for 10 days (cumulative dose 650 mg) did not experience any notable toxicity1 Electrocardiographic abnormalities were observed, but not often associated with significant cardiac symptoms2,3,4 T wave inversion (TWI) is the first to appe

  13. Slide 13: Emetine: Proposed Clinical Trial

    Emetine Emetine: Proposed Clinical Trial* Title: A Phase 2/3 Randomized, Blinded, Placebo-Controlled Clinical Study to Evaluate the Safety and Activity of Emetine Hydrochloride Injection, USP (ACER-2820) in High Risk, Symptomatic Adults with Confirmed SARS-CoV-2 Infection Not Requiring Hospitalizati

  14. Slide 14: Emetine: Regulatory Path

    Emetine Emetine: Regulatory Path Multiple Pre-IND briefing packages submitted to the Division of Antivirals (DAV) in April 2020 and June 2020 Discussions ongoing regarding requirements needed to submit IND Assuming FDA supports moving forward, Acer aims to submit IND followed by potential clinical t

  15. Slide 15: ACER-001 overview

    Small molecule with unique MOAs in various disorders UCDs: NaPB is a prodrug of phenylacetate, a NH4+ scavenger MSUD: NaPB is an allosteric inhibitor of BCKD kinase UCDs: A group of metabolic genetic diseases that lead to toxic build-up of NH4+ UCDs: Currently treated with RAVICTI®, BUPHENYL®, AMMON

  16. Slide 16: UCDs: Clinical Manifestations

    Newborns with severe urea cycle disorders become catastrophically ill with symptoms that mimic sepsis -- failure to feed, lethargy, respiratory distress, seizures and ultimately coma Children and adults with milder (or partial) urea cycle enzyme deficiencies may go years without a diagnosis, until a

  17. Slide 17: Phenylbutyrate: Mechanism of Action

    Berry S, et al. Pharmacokinetics of glycerol phenylbutyrate in pediatric patients 2 months T to 2 years of age with urea cycle disorders. Molecular Genetics and Metabolism 125 (2018) 251–257. ACER-001 Phenylbutyrate: Mechanism of Action Nitrogen scavenger therapy Alternative pathway treatment divert

  18. Slide 18: UCDs: Unmet Need

    ACER-001 UCDs: Unmet Need BUPHENYL®: Foul odor and foul/bitter taste; considered unpalatable* 64% of patients reported it is difficult to take because of taste Physicians reported that 25-33% of patients were prescribed less than target dose due to tolerability Only 25% of patients indicated that th

  19. Slide 19: NaPB: Food Effect

    ACER-001 NaPB: Food Effect 1 https://www.hzndocs.com/BUPHENYL-Prescribing-Information.pdf 2 https://www.hzndocs.com/RAVICTI-Prescribing-Information.PDF Absorption: Peak plasma levels of phenylbutyrate occur within 1 hour after a single dose of 5 grams of sodium phenylbutyrate tablet with a Cmax of 2

  20. Slide 20: NaPB: Food Effect data

    ACER-001 NaPB: Food Effect *Based on data comparison of ACER-001 under fed conditions vs. published data of NaPB under fed conditions 1 ACER-001 Pivotal BE/BA Study (Part B) 2 Sci Rep 9, 17075 (2019). https://doi.org/10.1038/s41598-019-53628-x Maximum concentration (Cmax) ~2x higher under fasted/pre

  21. Slide 21: ACER-001 PK: In Silico Model

    ACER-001 PK: Rosa & Co. In Silico Model Adult Virtual Patient Child Virtual Patient PAA (Safety1,2,3) uPAGN (Efficacy) 1 Mol Genet Metab. 2013 Dec; 110(4): 446-453. 2 Pediatr Res. 1986 Nov; 20(11):1117-21. 3 Cancer. 1995 Jun 15; 75(12):2932-8. ACER-001 in a fasted state required ~30% less PBA to ach

  22. Slide 22: ACER-001 Food Effect: Summary

    Dosing and Administration for BUPHENYL®, RAVICTI® and PHEBURANE® are all instructed to be given with food There is a significant food effect with NaPB The pharmacokinetic (PK) and pharmacodynamic (PD) properties of RAVICTI® are indistinguishable in the fed or fasted states1 Dosing in a pre-meal sett

  23. Slide 23: ACER-001 UCDs: Clinical & Regulatory Paths

    BE trial under fasted conditions successfully completed in Q1 2020 Received FDA Type C meeting feedback in August 2020 BE trial under fed conditions: Plan to complete in Q1 2021$ 505(b)(2) NDA: anticipate submission Q2 2021$ pending successful outcome of BE trial under fed conditions, additional non

  24. Slide 24: ACER-001: Differentiation

    Phenylbutyrate Formulations ACER-0011 (Investigational) RAVICTI® BUPHENYL® Efficacy / Safety in UCDs ✓ ✓ ✓ Palatability / Compliance ✓ ✓ ✘2 Pricing (Per Patient Per Year) TBD, likely near BUPHENYL $200k-$1.2M3 (avrg ~$900K) $200k-$400k4 Formulation Multi-Particulate (Sachet) Oil (Tablespoons) Powder

  25. Slide 25: ACER-001: IP / Exclusivities

    ACER-001 ACER-001: IP / Exclusivities IP: Filed formulation and method of use patent application for UCDs (priority date Oct. 2016) Issued patents (US/EP): “Methods of modulation of branched chain acids and uses thereof” [US PATENT NO. 10,092,532] in MSUD In addition, we continue to pursue new paten

  26. Slide 26: EDSIVO overview

    EDSIVO™ has a unique pharmacological profile β2 and β3 adrenergic receptor agonist; selective β1 and ⍺2 adrenergic receptor antagonist; activates endothelial Nitric Oxide Synthase (eNOS) EDSIVO’s™ potential beneficial effects in vEDS thought to be through vascular dilatation and smooth muscle relaxa

  27. Slide 27: EDSIVO: Regulatory Timeline

    June 2019: Received CRL from FDA CRL stated it will be necessary to conduct an adequate and well-controlled trial to determine whether celiprolol reduces the risk of clinical events in patients with vEDS December 2019: Submitted Formal Dispute Resolution Request (FDRR) to the Office of New Drugs (ON

  28. Slide 28: FDA: Substantial Evidence of Effectiveness

    EDSIVO™ FDA: Substantial Evidence of Effectiveness Two adequate and well-controlled clinical investigations2 One adequate and well-controlled investigation plus confirmatory evidence2 One adequate and well-controlled investigation1 THE QUANTITY OF CLINICAL EVIDENCE TO ESTABLISH EFFECTIVENESS In many

  29. Slide 29: Vascular Ehlers-Danlos Syndrome (vEDS)

    Ehlers-Danlos syndrome (EDS) is a group of hereditary disorders of connective tissue vEDS (EDS type IV) is the severe subtype: Characterized by aneurysms, dissections and/or ruptures Vascular Hollow Organs (e.g. gastrointestinal, uterine) Autosomal dominant (50%); spontaneous mutations (50%) Diagnos

  30. Slide 30: EDSIVO Unique Mechanism of Action

    Cardiology in Review 2017;25: 247–253. *Hypertension 2003 Nov;42(5):1004-13. EDSIVO™ has a unique pharmacological profile: β2 and β3 adrenergic receptor agonist Selective β1 and ⍺2 adrenergic receptor antagonist Intrinsic sympathomimetic activity (ISA+) Lacks non-specific membrane effects Activates

  31. Slide 31: EDSIVO BBEST Trial: COL3A1+ Subpopulation

    Efficacy: 76% reduction in the risk of fatal or nonfatal cardiac or arterial events in COL3A1+ EDSIVO™ patients vs. control group over mean follow-up of 47 months 75% reduction in risk of primary (cardiac or arterial events) and secondary (intestinal or uterine rupture) events in COL3A1+ EDSIVO™ pat

  32. Slide 32: Osanetant overview

    Osanetant is a selective, non-peptide tachykinin NK3 receptor antagonist NK3R is the main receptor for neurokinin B (NKB), a tachykinin peptide primarily found in the arcuate nucleus (ARC) of the hypothalamus Induced Vasomotor Symptoms (iVMS) iVMS are well documented with the use of cancer therapies

  33. Slide 33: Osanetant History

    Acer acquired worldwide rights to osanetant from Sanofi in December 2018 Osanetant (SR142801) was the first selective non-peptide tachykinin NK3 receptor antagonist evaluated as a potential treatment for schizophrenia Clinical and laboratory safety results are available from 21 completed Phase 1 and

  34. Slide 34: Vasomotor Symptoms (VMS): Overview

    VMS, typically comprised of hot flashes and night sweats, are associated with decreases in reproductive hormones commonly associated with menopause (e.g. MR-VMS) Osanetant Vasomotor Symptoms (VMS): Overview The Oncologist, Oct 2003, vol.8 no.5 474-487. http://www.everydayhealth.com/menopause/science

  35. Slide 35: Induced Vasomotor Symptoms (iVMS)

    Osanetant Induced Vasomotor Symptoms (iVMS) Women with HR+ Breast Cancer (CaB) receiving Tamoxifen 84% of women experienced hot flashes1 80% experienced night sweats 60% experienced severe symptoms Symptoms persisted throughout 5 years of treatment and were mainly attributed to tamoxifen After 4.5 y

  36. Slide 36: iVMS: The Unmet Need

    Osanetant iVMS: The Unmet Need iVMS are well documented with the use of cancer therapies and certain surgical procedures Symptoms such as hot flashes can appear immediately and be severe Non-adherence to cancer therapy can be associated with side effects which increases the mortality risk or shorten

  37. Slide 37: NK3 Receptor (Neurokinin B)

    Neurokinin B (NKB) belongs to a group of neuropeptides, called tachykinins or neurokinins, that includes substance-P (SP), neurokinin A (NKA), and two N-terminally extended forms of NKA, neuropeptide g and neuropeptide K The biological effects of tachykinins are mediated through specific receptors d

  38. Slide 38: NK3R Antagonist Clinical POC in VMS (fezolinetant)

    Osanetant NK3R Antagonist Clinical POC in VMS Herman Depypere et al., ENDO2017. Fezolinetant is a NK3R antagonist being developed by Astellas for moderate-to-severe VMS At Week 4: fezolinetant group: 14/40 patients have ZERO hot flash placebo group: 2/40 patients have ZERO hot flash Average Daily Ho

  39. Slide 39: NK3R Antagonist Clinical POC in VMS (pavinetant)

    Osanetant NK3R Antagonist Clinical POC in VMS Prague J., et al. Menopause. 2018 Aug;25(8):862-869. Pavinetant (MLE4901) was a NK3R antagonist that was discontinued by Millendo for the treatment of polycystic ovary syndrome and menopausal hot flushes % change from baseline Hot flash frequency Hot fla

  40. Slide 40: Osanetant: Clinical Development Plan

    Acer is partnering with leading universities to design & conduct clinical trials to evaluate osanetant in various patient populations with iVMS These include patients with medically or surgically iVMS (may include any/all of the following): Women who are BRCA+ and have had a PBSO Men with HR+ Prosta

  41. Slide 41: Osanetant: Exclusivity / Timelines

    Additional exclusivity (e.g. Orphan Drug Designation) will depend upon indication(s) and development pathway chosen Anticipate IND submission and initiation of Phase 1/2 trial in H1 2021, subject to additional capital Osanetant Osanetant: Exclusivity / Timelines

  42. Slide 42: Financial Overview

    Cash $5.9 million as of June 30, 2020, combined with $4.7 million of net proceeds raised from ATM facility and insider PIPE after June 30, 2020 Expected to have sufficient capital to fund current operations into Q1 2021, excluding support for the planned emetine Phase 2/3 clinical trial Capitalizati

  43. Slide 43: Summary

    Summary ACER *Subject to successful IND submission and clearance $Subject to additional capital **Assuming successful outcomes of BE trial under fed conditions, additional nonclinical work and long-term stability data Acer’s pipeline includes four clinical-stage product candidates: Emetine for the t

  44. Slide 44: Reference Slides

    acertherapeutics Reference Slides

  45. Slide 45: Maple Syrup Urine Disease (MSUD)

    MSUD is an inborn error of Branched-chain Amino Acid (BCAA) – leucine, isoleucine, valine – metabolism Caused by deficiency of the mitochondrial Branched-chain Keto Acid Dehydrogenase complex (BCKDC) ~800 patients in U.S., ~3,000 patients worldwide MSUD Family Support Group has >500 patients Part of

  46. Slide 46: ACER-001 MSUD: Clinical POC

    ACER-001 MSUD: Clinical POC Study Design: Open label pilot study1 at Baylor College of Medicine – 3 healthy and 5 MSUD subjects with late onset disease 3 days of steady-state protein diet*; then 3 days of NaPB + diet* BCAAs and BCKAs determined at day 3 of each study period (4 time points) Results:

  47. Slide 47: MSUD: Market Opportunity

    About 1,000 MSUD patients in the U.S., ~3,000 WW* 20-25% MSUD patients in U.S. are Mennonite; incidence up to 1/380 Ashkenazi Jewish population; incidence of 1/26,000 No treatments currently approved for MSUD Early treatment may help reduce the rate of neuropsychological comorbidities and optimize g

Acer Therapeutics — Investor Presentation (September 2020) on 6ix